Briefly, “donors” were implanted with MB49 and treated with either JHU083 or vehicle, then these tumor specimens were resected and viable TAMs (CD45+CD3−Ly6G−CD11b+F4/80+) were sorted, combined with fresh in vitro cultured MB49 cells at a 1:1 ratio, and implanted in the flanks of syngeneic “recipients” (Fig. 1J and K). This evidence concerns the gene PTPRC and neoplasm.